Hidradenitis Suppurativa

Karl Yen of Sanofi discussed the role of amlitelimab in AD following sustained results and a promising safety profile presented in data at AAD.

Novartis highlighted key findings at AAD and AAAAI, showcasing Cosentyx's flexible dosing for hidradenitis suppurativa and remibrutinib’s efficacy for chronic spontaneous urticaria.

Efficacy, safety, and pharmacokinetic data support the use of vilobelimab in treating pyoderma gangrenosum and hidradenitis suppurativa.

Charrow shares insights in complex dermatology and her work in HS at the annual meeting.

Colleen Cotton, MD, shared clinical tips in treating HS in pediatric patients at the annual SPD Pre-AAD Meeting.

Alexandra P. Charrow, MD, FAAD, shares insights on the link between dermatology and irritable bowel disease at the AAD Annual Meeting.

Bimekizumab demonstrated long-term effectiveness in patients with HS, with over 85% maintaining response and reduced draining tunnels.

Patients with hidradenitis suppurativa experience knowledge gaps on effective treatments and addressing these gaps could help prevent tissue damage among patients.

A case study explores a rare overlap of hidradenitis suppurativa and porokeratosis, highlighting unique histopathology and complications.

As 2024 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in hidradenitis suppurativa this year.

Hidradenitis suppurativa requires clinical vigilance, empathy, and the courage to escalate therapy early.

The company stated INF904 disrupts inflammatory pathways with over 90% effectiveness, based on Phase 1 data.

Panelists discuss how current HS treatments, ranging from topical antibiotics to biologics, show varying degrees of efficacy in managing symptoms, while highlighting the need for individualized treatment approaches based on disease severity and patient factors.

Panelists discuss how hidradenitis suppurativa significantly impacts patients' quality of life through chronic pain, skin lesions, and social stigma, while remaining frequently misdiagnosed or diagnosed late due to low disease awareness among healthcare providers.

Dena Antowan shares her journey balancing pre-med life, managing HS, advocating on TikTok, and her vision for empathetic dermatologic care.

Unlike previous therapies, bimekizumab has shown continued efficacy at 48 and 96 weeks, offering long-term benefits to HS patients.

Older adults with higher genetic risk for HS show increased risks for coronary artery disease and diabetes, according to UK Biobank data.

The pivotal BE HEARD trials demonstrated bimekizumab’s efficacy, showing meaningful improvements over placebo in HS patients.

A novel study assessed the potential of 2 AI platforms in providing accurate information to patients with HS.

The drug is the first FDA-approved treatment for moderate to severe HS that selectively inhibits both IL-17A and IL-17F.

A recent analysis found primary closure in HS surgery has higher recurrence rates, while secondary intention healing avoids complications but prolongs recovery.

Post-hoc analysis demonstrated secukinumab's efficacy in addressing both HS and HS-related psychiatric symptoms.

From diet recommendations to biologic advancements, Jennifer Hsiao, MD, covered essential updates for treating patients with HS.

A recent study revealed that patients with HS have a 23% prevalence of IA, emphasizing the need for routine screening in dermatologic practice.

A recent review found clinical trials for HS lack diversity, limiting understanding of treatment efficacy for SOC populations.

In this study, the highest infertility rate was seen in the patients living with hidradenitis suppurativa; however, no direct causality was seen for this, with the authors noting diseases and symptoms comprised the only factors with a statistically significant relationship to infertility.

This week’s collection of the latest dermatologic studies includes the potential association between hidradenitis suppurativa and infertility, refractory pediatric atopic dermatitis treated with dupilumab and abrocitinib, and omalizumab's efficacy in chronic inducible urticaria.

Nearly 44.2% of patients achieved HiSCR100, indicating a complete resolution of HS symptoms by the end of the 2-year period.

Researchers reported reductions in draining tunnels and total lesion counts.

In addition to decreases in BMI, researchers also reported fewer HS flare ups.